{"id":21248,"date":"2013-04-01T12:09:32","date_gmt":"2013-04-01T12:09:32","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=21248"},"modified":"2013-04-03T09:23:57","modified_gmt":"2013-04-03T09:23:57","slug":"gilead-sciences-announces-fourth-quarter-and-full-year-2012-financial-results","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/21248","title":{"rendered":"Gilead Sciences announces fourth quarter and full year 2012 financial results"},"content":{"rendered":"<p><strong>On 4 February 2013, Gilead announced details of its antiviral product sales which increased 17 percent to $2.17 billion for the fourth quarter of 2012, up from $1.86 billion for the fourth quarter of 2011.<\/strong><\/p>\n<p>This reflects sales growth of 20 percent in the U.S. and 9 percent in Europe.<\/p>\n<p>For 2012, antiviral product sales increased 15 percent to $8.14 billion from $7.05 billion in 2011, reflecting sales growth of 21 percent in the U.S. and 6 percent in Europe.<\/p>\n<p>Source: Gilead press release. Gilead Sciences announces fourth quarter and full year 2012 financial results. (4 February 2013).<\/p>\n<p><a href=\"http:\/\/www.gilead.com\/press\">http:\/\/www.gilead.com\/press<\/a><\/p>\n<p><a href=\"http:\/\/investors.gilead.com\/preview\/phoenix.zhtml?c=69964&amp;p=irol-newsArticle&amp;ID=1781144&amp;highlight=\">http:\/\/investors.gilead.com\/preview\/phoenix.zhtml?c=69964&amp;p=irol-newsArticle&amp;ID=1781144&amp;highlight=<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 4 February 2013, Gilead announced details of its antiviral product sales which increased 17 percent to $2.17 billion for the fourth quarter of 2012, up from $1.86 billion for the fourth quarter of 2011. This reflects sales growth of &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-21248","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/21248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=21248"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/21248\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=21248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=21248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=21248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}